OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
CD123-targeted therapy in acute myeloid leukemia	51
What is the future of digital tools to help manage pain in sickle cell disease patients?	50
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	42
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management	42
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	34
Do we need more guidance on thrombophilia testing? Challenges and special considerations	31
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP	26
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic	24
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon	24
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	22
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	21
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome	20
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease	20
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	20
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly	20
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis	20
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	19
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future	17
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations	17
Managing complications secondary to Waldenström’s macroglobulinemia	17
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis	16
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	15
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A	15
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations	14
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia	13

Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	13
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors	13
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women	13
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	12
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B	12
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management	12
The future of siRNA-mediated approaches to treat von Willebrand disease	12
Patient-centered care in von Willebrand disease: are we there yet?	11
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19	11
Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!	11
Voxelotor for the treatment of sickle cell disease in pediatric patients	11
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients	11
Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia	11
New directions to develop therapies for people with hemophilia	11
Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review	11
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management	10
An expert spotlight on inferior vena cava filters	10
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes	10
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations	10
The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders	10
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours	10
A toolmaker’s perspective on CRISPR-directed gene editing as a therapeutic strategy for leukemia and beyond	10
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review	10
Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study	10
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies	9
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?	9
Immunodeficiency-associated Hodgkin lymphoma	8
Lived experience experts: a name created by us for us	8
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors	8
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia	8
Optimizing long-term joint health in the treatment of hemophilia	8
Rivaroxaban plus aspirin after lower–extremity revascularization	8
Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases	8
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	8
Bad players in AL amyloidosis in the current era of treatment	8
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria	8
Role of volumetric analyses on [¹⁸F]FDG PET/CT in pediatric Hodgkin lymphoma	7
MRI detection of brain abnormality in sickle cell disease	7
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	7
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura	7
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients	7
Advances in our understanding of genetic markers and targeted therapies for pediatric LCH	7
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions	7
Monoclonal antibodies used for the management of hemataological disorders	7
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions	7
Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study	7
Long-term follow-up of patients with hairy cell leukemia in the south of Iran	7
Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades	7
Hematological disorders in children with Down syndrome	7
An update on novel therapies for treating patients with arterial thrombosis	7

What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?	7
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS	7
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia	6
Problems faced by people with hemophilia aged 18–35 years in social life: a qualitative study	6
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	6
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis	6
Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway	6
Sickle cell disease in gulf cooperation council countries: a systematic review	6
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children	6
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding	6
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms	6
Exploring health disparities in diagnosing multiple myeloma	6
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?	6
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	6
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia	6
Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia	5
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes	5
Exploring the genetic relationship between deep vein thrombosis and plasma protein: a new research idea	5
Avapritinib for Systemic Mastocytosis	5
Identifying prognostic gene panels in acute myeloid leukemia	5
Targeting von Willebrand disease: the current status and future directions of management therapies	5
New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond	5
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma	5
Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review	5
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin	5
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma	5
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them	5
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia	5
HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response	5
NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy	5
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency	5
Challenges in the diagnosis of thrombotic thrombocytopenic purpura	5
Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States	4
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review	4
Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma	4
Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors	4
The role of staging in multiple myeloma	4
Nutritional status of patients with lymphoproliferative neoplasms before and after the first-line treatment	4
Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia	4
The past, the present and the future of immune checkpoints inhibitors in multiple myeloma	4
Addressing unmet needs in rare bleeding disorders: selected poster extracts of recent research in hemophilia A and von Willebrand disease presented at the 14th Annual Congress of the European Associat	4
CircPTK2 promotes cell viability, cell cycle process, and glycolysis and inhibits cell apoptosis in acute myeloid leukemia by regulating miR-582-3p/ALG3 axis	4
Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload	4
Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension	4
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	4
Procalcitonin as a diagnostic marker for infection in sickle cell disease	4
Advances in viral oncolytics for treatment of multiple myeloma – a focused review	4
Long non-coding RNA LOC644135 is a potential prognostic indicator in cytogenetically normal acute myeloid leukemia	4
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact	4
Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients	4
CD8+CD25+ Tregs as a predictor of glucocorticoid sensitivity in patients with immune thrombocytopenia	4
Five decades of successive establishment of hemophilia care in Thailand	4
A new decade awaits sticky platelet syndrome: where are we now, how do we manage and what are the complications?	4
Targeting CD123 in BPDCN: an emerging field	4
How clinicians and persons with hemophilia may approach shared decision-making	4
Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control tr	4
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?	4
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes	4
Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis	4
Magnitude of anemia and associated factors among adult patients at Baso Liben District: a cross-sectional study	4